SEC Filing Summary: Klotho Neurosciences, Inc. (KLTO)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Klotho Neurosciences, Inc. on August 12, 2025, covering events occurring on August 6, 2025. The Company is a Delaware corporation trading on The Nasdaq Stock Market LLC under the symbols KLTO (Common Stock) and KLTOW (Warrants). The filing reports the entry into a material definitive agreement regarding the development of its gene therapy candidate.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figures disclosed relate to the new agreement:
- Initial Fees: $250,000 payable to AAVnerGene Inc.
- Royalty Obligation: 2% of revenue from all products created using the AAVone platform.
- Additional Fees: Applicable based on the stage of clinical trials (specific amounts not disclosed).
Material Changes
The primary material change is the execution of a Letter Agreement with AAVnerGene Inc. on August 6, 2025. This agreement secures the manufacturing and development of the Company's KLTO-202 gene therapy candidate utilizing AAVnerGene's platform technology. This represents a strategic partnership to advance the Company's clinical pipeline.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding future commercial operations and the implementation of business plans. Management highlights several risks and uncertainties that could cause actual results to differ materially from projections, including:
- Inability to implement business plans or realize opportunities.
- Failure to meet financial projections.
- Changes in the regulatory or competitive environment.
The Company explicitly states it undertakes no obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the full terms of the Letter Agreement (Exhibit 4.1) regarding milestone payments and termination clauses.
- Confirm the current cash position of Klotho Neurosciences to assess the ability to fund the $250,000 initial fee and future clinical trial costs.
- Review the status of the KLTO-202 candidate and the specific timeline for clinical trial stages triggering additional fees.
- Examine the definition of "revenue" within the agreement to understand the scope of the 2% royalty obligation.